Incretin-Based Therapies for Type 2 Diabetes: Clinical Utility

Robert Ratner

Tài liệu tham khảo

Drucker, 2006, The biology of incretin hormoness, Cell Metab, 3, 153, 10.1016/j.cmet.2006.01.004 Buse, 2004, Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes, Diabetes Care, 27, 2628, 10.2337/diacare.27.11.2628 Kendall, 2005, Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea, Diabetes Care, 28, 1083, 10.2337/diacare.28.5.1083 DeFronzo, 2005, Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes, Diabetes Care, 28, 1092, 10.2337/diacare.28.5.1092 Ratner, 2006, Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus, Diabetes Obes Metab, 8, 419, 10.1111/j.1463-1326.2006.00589.x Ratner, 2005, Exenatide maintains glycemic control for 2 years in patients with type 2 diabetes: data from an ongoing open label study, Diabetologia, 48, A228 Zinman B, et al. Presented at the 66th Scientific Session of the American Diabetes Association, June 9–13, 2006, Washington, DC. Abstract 117-OR. Heine, 2005, Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial, Ann Intern Med, 143, 559, 10.7326/0003-4819-143-8-200510180-00006 Fehse, 2005, Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes, J Clin Endocrinol Metabol, 90, 5991, 10.1210/jc.2005-1093 Herman GA, et al. Presented at the 64th Scientific Session of the American Diabetes Association, June 4–8, 2004, Orlando, Florida. Abstract 353-OR. Herman, 2005, Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses, Clin Pharmacol Ther, 78, 675, 10.1016/j.clpt.2005.09.002 Brazg RL, et al. Presented at the 65th Scientific Session of the American Diabetes Association, June 10–14, 2005, San Diego, California. Karasik A, et al. Presented at the 66th Scientific Session of the American Diabetes Association, June 11, 2006, Washington, DC. Abstract 020. Rosenstock J, et al. Presented at the 66th Scientific Session of the American Diabetes Association, June 11, 2006, Washington, DC. Abstract 019. Duttaroy, 2005, The DPP-4 inhibitor vildagliptin increases pancreatic beta cell neogenesis and decreases apoptosis, Diabetes, 54, A141 Ahren B. Presented at the 64th Scientific Session of the American Diabetes Association, June 4–8, 2004, Orlando, Florida. Late Breaking Trials. Ahren, 2004, Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin treated patients with type 2 diabetes, Diabetes Care, 27, 2874, 10.2337/diacare.27.12.2874